hier.

Prof. Dr. med. Eckhart Weidmann
Literaturverzeichnis
Bergmann L, Mitrou PS, Demmer-Dieckmann M, Ruhmann FT, Weidmann E: Impaired T- and B cell function
in Hodgkin's disease. Reduced mitogenic responsibility and IL-2 production is not caused by defective CD4+
cells. Cancer Immunol Immunother 25 (1987) 59-64.
Bergmann L, Mitrou PS, Weidmann E, Schmidt-Matthiesen A, Hanke P, Hoelzer D: In vitro and in vivo
induction of lymphokine activated killer cells (LAK cells) in patients with gastric cancer and other malignant
diseases. In Koldovsky et al. (eds.): Lymphocytes in immunotherapy of cancer: Springer Verlag, Berlin, New
York (1989) 32-40.
Bergmann L, Weidmann E, Bungert B, Hechler P, Mitrou PS: Influence of various cytokines
on the induction of lymphokine activated killer cells. Nat Immun Cell Growth Regul 9 (1990)
265-273.
Bergmann L, Weidmann E, Mitrou PS, Runne U, Keilholz U, Bartsch HH, Franks CR:
Interleukin 2 in combination with Interferon- in disseminated malignant melanoma and renal
cell carcinoma. A phase I/II study. Onkologie 13 (1990) 137-140.
Bergmann L, Weidmann E, Mitrou PS: Immuntherapie des fortgeschrittenen
Nierenzellkarzinoms. Dtsch Med Wschr 116 (1991) 384-390.
Weidmann E, Bergmann L, Hechler P, Mitrou PS: Cytotoxic activity and phenotypic
characteristics of lymphocyte subsets after therapy of cancer with interleukin 2. Cancer
Immunol Immunother 33 (1991) 398-402.
Bergmann L, Weidmann E, Enzinger HM, Fenchel K, Jonas D, Mitrou PS: Interleukin 2 and
interferon-alpha as a daily alternating schedule in advanced renal cell cancer. Preliminary
results of a phase II study. World J Urol 9 (1991) 215-218.
Shimizu Y, Weidmann E, Iwatsuki S, Herberman RB, Whiteside TL: Characterization of
human autotumor-reactive T cell clones obtained from tumor infiltrating lymphocytes in liver
metastasis of gastric carcinoma. Cancer Res 51 (1991) 6153-6162.
Weidmann E, Bergmann L, Stock J, Kirsten R, Mitrou PS: Rapid cytokine release in cancer
patients treated with Interleukin 2. J Immunother. 12 (1992) 123-131.
Weidmann E, Whiteside TL, Giorda R, Herbermann RB, Trucco M: The T cell receptor Vß
usage in tumor infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.
Cancer Res 52 (1992) 5913-5920.
Weidmann E, Sacchi M, Plaisance S, Heo DS, Yasumura S, Lin W, Johnson JT, Herberman
RB, Azzarone B, Whiteside TL: Receptors for interleukin 2 (IL2R) on human squamous cell
carcinoma cell lines and tumor in situ. Cancer Res 52 (1992) 5963-5970.
Weidmann E, Bergmann L, Hechler P, Schwulera U, Grieser H, Mitrou PS: Interleukin 2 in
the treatment of cancer disease: Introduction af a therapeutic model and some immunological
data. In Fleischer (ed.): Leukemia. Springer-Verlag Heidelberg, Berlin (1993) 111-116.
Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS: Daily
alternating administration of high dose interferon- and interleukin 2 bolus infusion in
metastatic renal cell cancer. A phasa II study. Cancer 72 (1993) 1733-1742.
Keilholz U, Schreibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, Richter M,
Brado B, Mitrou PS, Hunstein W: Interferon- and interleukin 2 in the treatment of metastatic
melanoma: Comparison of two phase II trials. Cancer 72 (1993) 607-614.
Weidmann E, Elder EM, Trucco M, Lotze MT, Whiteside TL: Usage of the T cell receptor
beta chain genes in fresh and cultured tumor infiltrating lymphocytes from human melanoma.
Int J Cancer 54 (1993) 383-390.
Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL: Evidence for
oligoclonal T cell response in a metastasis of renal cell carcinoma responding to vaccination
with autologous tumor cells and transfer of in vitro sensitized vaccine draining lymph node
lymphocytes. Cancer Res 53 (1993) 4745-4749.
Weidmann E, Elder EM, Herberman RB, Trucco M, Whiteside TL: The T cell receptor beta
chain variable region repertoire in fresh and cultured lymphocytes isolated from malignant
melanoma. In Bergmann L, Mitrou PS (eds.): Contributions to oncology: Cytokines in cancer
therapy. Karger Verlag, Basel 46 (1994) 133-142.
Keilholz U, Schreibenbogen C, MacLachlan D, Jochim A, Bergmann L, Weidmann E,Mitrou
PS, Tilgen W, Hunstein W: Treatment of malignant melanoma with interferon alpha and high
dose interleukin 2. In Bergmann L, Mitrou PS (eds.): Contributions to oncology: Cytokines in
cancer therapy. Karger Verlag, Basel 46 (1994) 191-198.
Weidmann E, Trucco M, Whiteside TL: Relevance of the T cell receptor for immunotherapy
of cancer. Cancer Immunol Immunother 39 (1994) 1-14.
Conrad B, Weidmann E, Trucco G, Rudert WA, Behboo R, Ricordi C, Rodrigues Rilo H,
Feingold D, Trucco M: Evidence for superantigen involvement in insulin-dependent diabetes
mellitus aetiology. Nature 371 (1994) 351-355.
Yasumura S, Weidmann E, Hirabayashi H, Johnson JT, Herberman RB, Whiteside TL: HLA
restriction and T cell receptor Vß gene expression of cytotoxic T lymphocytes reactive with
human squamous cell carcinoma of the head and neck. Int J Cancer 57 (1994) 297-305.
Yasumura S, Lin WC, Weidmann E, Hebda P, Whiteside TL: Expression of interleukin 2
receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2. Int J
Cancer 59 (1994) 225-234.
Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L: The expression of
the Wilms tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast
cells. Leukemia 8 (1994) 2138-2143.
Jahn B, Bergmann L, Weidmann E, Brieger J, Fenchel K, Schwulera U, Hoelzer D, Mitrou
PS: Bone marrow derived T cell clones of previously untreated acute myelocitic leukemia
with blast directed autologous cytotoxicity. Leukemia Res 19 (1995) 73-82.
Weidmann E, Brieger J, Jahn B, Hoelzer D, Bergmann L, Mitrou PS: Lactate dehydrogenase release assay. A
reliable, non-radioactive technique for analysis of cytotoxic lymphocyte mediated lytic activity against blasts
from acute myelocytic leukemia. Ann Hematol 70 (1995) 153-158.
Weidmann E, Brieger J, Bergmann L, Hoelzer D, Mitrou PS: AML blasts variably express interleukin 2
receptor  or  chains without measurable effects on proliferation, cytokine message expression or surface
expression of adhesion molecules upon stimulation with interleukin 2. Leukemia Res 19 (1995) 469-476.
Brieger J, Weidmann E, Maurer U, Hoelzer D, Mitrou PS, Bergmann L: The Wilms` tumor gene is frequently
expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR.
Ann Oncol 6 (1995) 811-816.
Bergmann L, Schui DK, Brieger J, Weidmann E, Mitrou PS, Hoelzer D: The inhibition of ymphokine-activated
killer cells is mediated by transforming growth factor-1. Exp Hematol 23 (1995) 1574-1580.
Weidmann E, Brieger J, Fenchel K, Hoelzer D, Bergmann L, Mitrou PS: IL-2 receptor alpha, beta and gamma
chains expressed on blasts of acute myelocytic leukemia may not be functional. Acute Leukemias V.
Experimental approaches and management of refractory diseases. Hiddemann et al., (Eds.) (1996) 542-546.
Brieger J, Weidmann E, Fenchel K, Mitrou PS, Bergmann L, Hoelzer D: The amplification of the Wilms tumor
gene (wt-1) mRNA using the polymerase chain reaction technique (PCR) may enable sensitive detection of small
blast populations in AML. Acute Leukemias V. Experimental approaches and management of refractory
diseases. Hiddemann et al., (Eds.) (1996) 501-505.
Schui DK, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L: The inhibition of lymphokine-activated
killer cell activation mediated by AML culture supernatants might be due to transforming growth factor beta 1.
Acute Leukemias V. Experimental approaches and management of refractory diseases. Hiddemann et al., (Eds.)
(1996) 294-297.
Weidmann E: Gentransfer als neues Therapieprinzip hämato-onkologischer Neoplasien. In: Zytokine (Niederle,
Bergmann, Ganser, eds.) Fischer Verlag, Jena (1996) 238-250.
Karakas T, Bergmann L, Stutte HJ, Jäger E, Knuth A, Weidmann E, Mitrou PS, Hoelzer D: Peripheral T-cell
lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and
have a similar outcome as high-grade B-cell lymphomas. Leukemia and lymphoma 24 (1996) 121-129.
Brieger J, Weidmann E, Maurer U, Mitrou PS, Hoelzer D, Bergmann L: Detection of the Wilms’ tumor gene
(wt-1) mRNA in complete remission of AML frequently precedes relapse. Acute Leukemias VI. Prognostic
factors and tratment strategies. Büchner T. et al., (Eds.) (1997) 120-124.
Weidmann E, Brieger J, Karakas T, Maurer U, Hoelzer D, Mitrou PS, Bergmann L: Establishment and
characterization of a new, factor independent FAB M2 acute myeloid leukemia line, Ei501. Leukemia 11 (1997)
709-713.
Bergmann L, Maurer U, Weidmann E: Wilms’ tumor gene expression in acute myeloid leukemias. Leukemia &
Lymphoma 25 (1997) 435-443.
Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L: The Wilms’ tumor gene is expressed in
a subset of CD34+ progenitors and downregulated early in course of differentiation in vitro. Exp Hematol 25
(1997) 945-950.
Begmann L, Miething CC, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D: High levels of Wilms’
tumor gene (wt1) RNA in acute myeloid leukemias are associated with a worse long term outcome. Blood 90
(1997) 1217-1225.
Maurer U, Weidmann E, Karakas T, Hoelzer D, Bergmann L: Wilms tumor gene (wt1) mRNA is equally
expressed in blast cells from acute myeloid leukemia and normal CD34 + Progenitors. Blood [letter] 90 (1997)
4230-4231.
Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L: High expression of bcl-2 mRNA
as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 9 (1998)159-165.
Raab C, Weidmann E, Schmidt A, Bergmann L, Badenhoop K, Usadel K-H, Haak T: The effects of interleukin
2 treatment on endothekin and the activation of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol 50
(1999) 37-44.
Klein SA, Ottmann OG, Ballas K, Dobmeyer TS, Pape M, Weidmann E, Hoelzer D, Kalina U: Quantification
of human interleukin 18 mRNA expression by competitive reverse transcriptase polymerase chain reaction.
Cytokine 11 (1999) 451-458.
Weidmann E, Baican B, Hertel A, Baum RP, Chow KU, Knupp B, Adams S, Hör G, Hoelzer D, Mitrou PS:
Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with
Hodgkin’s disease. Leukemia & Lymphoma, 34 (1999) 545-551.
Staszewski S, Miller V, Sabin C, Carlebach A, Berger A-B, Weidmann E, Helm EB, Hill A, Phillips A:
Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 13 (1999) 367-373.
Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidmann E, Hill A,
Phillips A: Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.
AIDS 13 (1999), 951-956.
Miller V, Staszewski S, Sabine C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Cozzi Lepri A,
Phillips AN: CD4 lymphocyte count as a predictor of the duration of HAART-induced suppression of HIV-1
virus load. J Infect Disease 180 (1999) 530-533.
Chow KU, Rummel MJ, Weidmann E, Ries J, Jantschke P, Boehrer S, Pourebrahim F, Martin H, Stein J,
Hoelzer D, Mitrou PS: Induction of apoptosis by 2-chloro-2’deoxyadenosine (2-CdA) alone and in combination
with other cytotoxic drugs. Synergistic effects on normal and neoplastic lymphocytes by addition of
doxorubicine and mitoxantrone. Leukemia and Lymphoma 36 (2000) 559-567.
Chow KU, Ries J, Weidmann E, Pourebrahim F, Napieralski S, Stieler M, Boehrer S, Rummel MJ, Stein J,
Hoelzer D, Mitrou PS: Induction of apoptosis by 2’,2’ difluorodeoxycytidine (gemcitabine) in combination with
antimetabolites or anthracyclins on malignant lymphatic and myeloid cells. Antagonism or synergism depends
on incubation schedule and origin of neoplastic cells. Ann Hematol 79 (2000) 485-492.
Weidmann E: Hepatosplenic T-cell lymphoma. A review on 45 cases since the first report describing the
disease as a distinct lymphoma entity in 1990. Leukemia 14 (2000) 991-997.
Viertel A, Weidmann E, Ditting T, Geiger H: Management of renal complications in patients with advanced
multiple myeloma. Leuk Lymphoma 38 (2000) 513-519.
Viertel A, Weidmann E, Wigand R, Geiger H, Mondorf UF: Treatment of severe systemic lupus erythematodes
with immunoadsorption and intravenous immunoglobulins. Intens Care Med 26 (2000) 823-824 [letter].
Viertel A, Weidmann E, Rickerts V, Scheuermann EH, Geiger H, Brodt HR: Renal involvement in HIV
infection. A review and a retrospective analysis of the Frankfurt AIDS cohort study. Eur J Med Res 5 (2000)
185-198.
Weidmann E, Hinz T, Klein SA, Schui DK, Harder S, Kriener S, Kabelitz D, Hoelzer D, Mitrou PS: Cytotoxic
Hepatosplenic  T-Cell Lymphoma Following Acute Myeloid Leukemia Bearing Two Distinct  Chains of the
T-Cell Receptor. Biologic and Clinical Features. Haematologica 85 (2000) 1024-1031.
Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB,
Staszewski S: The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of
HIV disease and ist relationship to CD4 and viral load. AIDS 14 (2000) 2129-2136.
Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D’Aquila R. Larder B, Lutz T, Gute P, Weidmann E,
Rabenau H, Phillips A, Staszewski S: Virological and immunological effects of treatment interuptions in HIV-1
infected patients with treatment failure. AIDS 14 (2000) 2857-2867.
Chow KU, Schneider B, Mitrou PS, Weidmann E: Influence of various cytokines on the expression of CD20 on
the surface of CLL-cells in vitro. Leuk Res 25 (2001) 99-100.
Maurer U, Jehan F, Englert C, Hubinger G, Weidmann E, DeLuca HF, Bergmann L: The Wilms’ tumor gene
product (Wt1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D-receptor
(VDR). J Biol Chem 276 (2001) 3727-3732.
Boehrer S, Hinz T, Schui DK, Harder S, Chow KU, Schneider B, Hoelzer D, Mitrou P.S., Weidmann E: T-large
granular lymphocyte leukemia with natural killer-cell-like cytotoxicity and expression of two different  and
TCR chains. Br J Haematol 112 (2001) 201-203.
Fauth F, Weidmann E, Martin H, Schneider B, Sonnhoff S, Hoelzer D. AC133 expression on acute myeloid
leukemia blasts: correlation to FAB and to CD34 expression and possible implications for peripheral blood
progenitor cell purging in AML, Leukemia Res 25 (2001) 191-196.
Boehrer S, Chow KU, Puccetti E, Ruthardt M, Godhzisard S, Krahpohl A, Schneider B, Hoelzer D, Mitrou PS,
Rangnekar VM, Weidmann E: Deregulated expression of prostate apoptosis response gene-4 (PAR-4) in less
differentiated lymphocytes and mutually exclusive patterns of Par-4 and Bcl-2 in acute lymphocytic leukemia.
Hematol J 2 (2001) 103-107.
Weidmann E, Boehrer S, Chow KU, Engels K, Harder L, Hinz T, Janssen O, Kriener S, Rummel MJ, Siebert R,
Kabelitz D, Hansmann ML, Hoelzer D, Mitrou PS: Treatment of Aggressive and Progressing Indolent Peripheral
T- and NK- Cell Neoplasias by Combination of Fludarabine, Cyclophosphamide and Doxorubicine Introduction of a Protocol by the „Study Group Peripheral T- and NK-Cell Neoplasias“. Onkologie 24 (2001)
162-164.
Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, Weidmann E: In vitro induction of
apoptosis of neoplastic cells in low-grade non-Hodgkin’s lymphomas using combinations of established
cytotoxic drugs with bendamustine. Haematologica 86 (2001) 485-493.
Mahlknecht U, Weidmann E, Seipelt G: Black tea delays recovery from iron deficiency anaemia.
Haematologica (2001) 559.
Hinz T, Weidmann E, Kabelitz D: Dual TCR-expressing T lymphocytes in health and disease. Int Arch Allergy
Immunol 125 (2001) 16-20.
Viertel A, Weidmann E, Brodt H-R: Akute Vergiftungen in der Internistischen Intensivmedizin. Dtsch Med
Wochenschr 126 (2001) 1159-1163.
Weidmann E: Differenzierung der Lymphozyten. In: Non-Hodgkin-Lymphome. Mitrou PS (Ed.)
Tumorzentrum Rhein/Main Selbstverlag (2001) 3-14.
Weidmann E: Molekularbiologische Grundlagen. In: Non-Hodgkin-Lymphome. Mitrou PS (Ed.)
Tumorzentrum Rhein/Main Selbstverlag (2001) 15-22.
Weidmann E, Engels K, Fellbaum C: Immunologische Typisierung von Lymphomen und Leukämien. In: NonHodgkin-Lymphome. Mitrou PS (Ed.) Tumorzentrum Rhein/Main Selbstverlag (2001) 25-34.
Weidmann E, Fellbaum C, Mitrou PS: Hochmaligne B-Zell Lymphome. In: Non-Hodgkin-Lymphome. Mitrou
PS (Ed.) Tumorzentrum Rhein/Main Selbstverlag (2001) 163-181.
Weidmann E, Mitrou P.S., Fellbaum C: Lymphome und Leukämien der T-Zellreihe In: Non-HodgkinLymphome. Mitrou PS (Ed.) Tumorzentrum Rhein/Main Selbstverlag (2001) 221-234.
Chow KU, Sommerlad D, Boehrer S, Schneider B, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E: AntiCD20 antibody (IDEC-C2B8, Rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in
vitro: role of cytokines, complement and caspases. Haematologica 87 (2002) 33-43.
Mitrou PS, Weidmann E, Rummel M: Non-Hodgkin-Lymphome (NHL). Teil I: Grundlagen,
Lymphozytendifferenzierung, Klassifikation, Diagnostik, Stadieneinteilung, Zytogenetik der NHL.
Arztneimitteltherapie 20 (2002) 14-23.
Chow KU, Boehrer S, Bojunga J, Stieler M, Rummel MJ, Fauth F, Schneider B, Martin H, Hoelzer D,
Weidmann E, Mitrou PS: Induction of apoptosis by cladribine, gemcitabine and other chemotherapeutic drugs
on CD34+/CD38+ and Cd34+/CD38- hematopoietic progenitor cells. Selective Effects by doxorubicin and
cladribine with protection of immature cells. Leuk & Lymphoma 43 (2002) 377-384.
Mitrou PS, Weidmann E, Rummel M: Non-Hodgkin-Lymphome. Teil III: Hochmaligne Lymphome und HIVassoziierte, primär extranodale Lymphome der B-Zell-Reihe. Arztneimitteltherapie 20 (2002) 105-115.
Mitrou PS, Weidmann E, Rummel M: Non-Hodgkin-Lymphome. Teil IV: Periphere Lymphome der TZellreihe, primäre kutane Lymphome. Arztneimitteltherapie, 20 (2002) 152-162.
Schui DK, Singh L, Schneider B, Krapohl A, Hoelzer D, Weidmann E: Inhibiting effects on the induction of
cytotoxic T-lymphocytes by dendritic cells pulsed with lysates from AML blasts. Leuk Res 26 (2002) 383-389.
Boehrer S, Chow KU, Beske F, Kukoc-Zivojnov N, Puccetti E, Ruthardt M, Baum C, Rangnekar VM, Hoelzer
D, Mitrou PS, Weidmann E: In lymphatic cells Par-4 sensitizes to apoptosis by down-regulating Bcl-2 and
promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 62 (2002) 17681775.
Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D, Bergmann L: The coexpression
of the apoptosis-related genes bcl-2 and wt1 in predicting survival in acute myeloid leukemia. Leukemia 16
(2002) 846-854.
Boehrer S, Chow KU, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E: Expression and function of prostateapoptosis-response-gene-4 in lymphatic cells. Leuk Lymphoma 43 (2002) 1737-1741.
Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E: In vitro studies with bendamustine: Enhanced
activity in combination with rituximab. Semin Oncol 29 (2002; suppl. 13) 12-14.
Weidmann E, Kim S-Z, Rost A, Seiperlt G, Hoelzer D, Mitrou PS: Bendamustin is effective in relapsed or
refractory high-grade non-Hodgkin’s lymphoma. Ann Oncol 13 (2002) 1285-1289.
Boehrer S, Schui DK, Chow KU, Hoelzer D, Mitrou PS, Weidmann E: Cytotoxic
activity of T- and NK-cell lymphoma cells is not dependent on an mature cytotoxic
phenotype. Leuk Lymphoma 43 (2002) 2363-2368.
Chow KU, Boehrer S, Napieralski S, Nowak D, Knau A, Hoelzer D, Mitrou PS, Weidmann E: In AML cell
lines ara-c combined with purine analogues is able to exert synergistic as well as antagonistic effects on
proliferation, apoptosis, and disruption of mitochondrial membrane potential. Leuk Lymphpoma 44 (2003) 165173.
Chow KU, Nowak D, Boehrer S, Ruthard M, Knau A, Hoelzer D, Mitrou PS, Weidmann E: Synergistic effects
of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis
proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced
caspase activation. Biochem Pharmacol 66 (2003) 711-724.
Kim, SZ, Zollner TM, Schui DK, Chow KU, Sterry W, Kriener S, Hoelzer D, Mitrou PS, Weidmann E:
CD4+/CD56+ neoplasia. Clinical features with emphasis on cytotoxic drug-induced apoptosis and expression of
sialyl Lewis X. Leuk Lymphoma 44 (2003) 281-289.
Weidmann E, Gramatzki M, Wilhelm M, Mitrou PS: Diagnosis and actual therapy strategies in peripheral Tcell lymphomas – summary of an international meeting. Ann Oncol 15 (2004) 369-374.
Boehrer S, Brieger A, Schaaf S, Kukoc-Zivojnov N, Nowak D, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann
E, Chow KU: In the erythroleukemic cell line HEL prostate-apoptosis-response-gene-4 (Par-4) fails to downregulate bcl-2 and to promote apoptosis. Leuk Lymphoma 45 (2004) 1445-1451.
Kukoc-Zivojnov N, Puccetti E, Chow KU, Bergmann M, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E,
Boehrer S: Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185BCR-ABL in
hematopoietic cells. Exp Hematol 32 (2004) 649-656.
Nowak D, Boehrer S, Brieger A, Kim SZ, Schaaf S, Hoelzer D, Mitrou PS, Weidmann E, Chow KU. Upon
drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol
to the nucleus. Leuk Lymphoma 45 (2004) 1429-1436.
Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, Atadja P, Hoelzer D, Mitrou PS, Weidmann E,
Chow KU. In BCR-ABL-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of
Par-4 increases sensitivity to imatinib (STI571) and histone-deacetylase inhibitors. Biochemical Pharmacology
68 (2004) 85-93.
Weidmann E, Gramatzki M, Wilhelm M, Mitrou PS: Diagnosis and actual therapy strategies in peripheral Tcell lymphomas – summary of an international meeting. Ann Oncol (South African Exerpts Edidion) 1 (2004)
117-122 (published on request of Ann Oncol).
Boehrer S, Nowak D, Schaaf S, Bergmann M, Brieger A, Hoelzer D, Mitrou PS, Weidmann E, Chow KU. In
malignant myeloid cells expression of DAXX down-regulates expression of p53 and of the inhibitors of
apoptosis proteins. Hematol J 5 (2004) 513-518.
Kim SZ, Chow KU, Kukoc-Zivojnov N, Boehrer S, Brieger A, Steimle-Grauer SA, Harder L, Hoelzer D, Mitrou
PS, Weidmann E. Expression of ZAP-70 protein correlates with disease stage in chronic lymphatic leukemia
and is associated with, but not generally restricted to, non-mutated Ig VH status. Leuk Lymphoma 45 (2004)
2037-2045.
Bergmann M, Kukoc-Zivojnov N, Chow KU, Trepohl B, Hoelzer D, Weidmann E, Mitrou PS, Boehrer S.
Prostate-apoptosis-response-gene-4 sensitizes neoplastic lymphocytes to CD95-induced apoptosis. Ann Hematol
83 (2004) 646-653.
Weidmann E: T-Zell-Lymphome. In: Lymphome. Hiddemann W, Dreyling M, Stein H (Eds.) Georg ThiemeVerlag, Stuttgart, New York (2005) 133-156.
Boehrer S, Kukoc-Zivojnov, Nowak D, Bergmann M, Baum C, Puccetti E, Weidmann E, Hoelzer D, Mitrou
PS, Chow KU. Upon drug-induced apoptosis expression of prostate-apoptosis-response-gene-4 promotes
cleavage of caspase-8, bid and mitochondrial release of cytochrome C. Hematology 9 (2004) 425-431.
Boehrer S, Nowak D, Kukoc-Zivojnov N, Hochmuth S, Kim SZ, Hoelzer D, Mitrou PS, Weidmann E, Chow
KU. Expression of DAXX sensitizes Jurkat T-cells to the apoptosis-inducing effect of chemotherapeutic agents.
Pharmacol Res 51 (2005) 367-374.
Boehrer S, Nowak D, Hochmuth S, Kim SZ, Trepohl B, Afkir A, Hoelzer D, Mitrou PS, Weidmann E, Chow
KU. DAXX overexpression in T-lymphoblastic Jurkat cells enhances caspase-dependent death receptor- and
drug-induced apoptosis in distinct ways. Cell Signal 17 (2005) 581-595.
Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM,
Knuth A, Jager E. Intratumoral T-cell infiltrates and MHC class 1 expression in patients with stage IV
melanoma. Cancer Res 65 (2005) 3937-3941.
Chow KU, Nowak D, Kim SZ, Schneider B, Komor M, Boehrer S, Mitrou PS, Hoelzer D, Weidmann E,
Hofmann WK. In vivo drug-response in patients with leukemic non-Hodgkin’s lymphomas is associated with in
vitro chemosensitivity and gene expression profiling. Pharmacol Res 53 (2006) 49-61.
Weidmann E, Mitrou PS. Periphere T-Zell-Lymphome. In: Kompendium Internistische Onkologie; 4. Auflage.
Schmoll H-J, Höffken K, Possinger K (Eds.). Springer Verlag (2006) 3048-3065.
Willenbrock K, Küppers R, Renné C, Brune V, Eckerle S, Weidmann E, Bräuninger A, Hansmann ML.
Common features and differences in the transcriptosome of large cell anaplastic lymphoma and classical
Hodgkin’s lymphoma. Haematologica 91 (2006) 596-604.
Friedmann I, Atmaca A, Chow KU, Jäger E, Weidmann E. Synergistic effects of valproic acid and mitomycin C
in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother 18 (2006) 415420.
Rickerts V, Brodt HR, Schneider B, Weidmann E, Chow KU. Host factors and disease severity in two patients
with SARS. Wirtsfaktoren und Erkrankungsschwere in zwei Patienten mit SARS. Laboratoriumsmedizin 30
(2006) 18-22.
Al-Batran SE, Kerber A, Atmaca A, Dechow C, Reitsamer E, Schmidt S, Kolassa Y, Neumann A, Weidmann
E, Hartmann JT, Jäger E. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for
patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial. Onkologie30 (2007) 2934.
Atta J, Chow KU, Weidmann E, Mitrou PS, Hoelzer D, Martin H. Dexa-Beam as salvage therapy in patients
with primary refractory aggressive Non-Hodgkin lymphoma. Leuk Lymphoma 48 (2007) 349-356.
Weidmann E, Jäger E. Tumor-Escape-Mechanismen. In: Krebsimmuntherapien. Standards und Innovationen.
Huber C, Rammensee H-G, Wölfel T, Britten CM (eds.) Deutscher Ärzteverlag Köln (2008) 67-67.
Bender A, Karbach J, Neumann A, Jager D, Al-Batran SE, Atmaca A, Weidmann E, Biskamp M, Gnatic S, Pan
L, Hoffmann E, Old LJ, Knuth A, Jager E. LUD 00-009: phase 1 study of intensive course immunization with
NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1 expressing cancer. Cancer Immun 7 (2007) 16
Weidmann E. T-Zell-Lymphome. In: NHL Diagnostik und Therapie – State of the Art 2007. Rummel MJ (ed.)
Agileum Verlag und Gesundheitsakademie, München (2008) 253-266.
Weisel KC, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M. Epstein-Barr virus-associated
B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. Int J Hematol 88
(2008) 434-440.
Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ulrich K, Hiddemann W,
Dreyling M. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed
and refractory mantle cell lymphoma – long term results of a multicenter observation study. Leuk Lymphoma 50
(2009) 716-722.
Weidmann E, Jäger E. Krebserkrankungen mit unbekanntem Primärtumor (CUP). In: Die Onkologie; 2.
Auflage. Hiddemann W, Bartram C (eds.) Springer Verlag, Heidelberg (2009) 1778-1790.
Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki
NK, Jäger E. Tumor-reactive CD8(+) T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and
Montanide® ISA-51: Association with survival. Int J Cancer 126 (2010) 909-918.
Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Soekler M, Kim SZ, Napieralski S, Rech
J, Dreyling M, Jäger E, Mitrou PS. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and
doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma 51 (2010) 447-455.
Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jäger E. Phase II study of
Bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive
B-cell lymphomas. Ann Oncol 22 (2011) 1839-1844.
Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig
R, Heits F, Lordick F, Rösler W, Petersen P, Wehler D, Zander AR, Albert M, Dressler S, Ebinger M,
Frickhofen N, Hertenstein B, Kiel M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F,
Kröger N. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate
use programme. Bone Marrow Transplantation 46 (2011) 1045-1052.
Rummel MJ, Niederle N, Maschmeyer G, Banat A, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G,
Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke
A, Brugger W. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with
indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Lancet 381 (9873) (2013) 1203-1210.
Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe
A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P. ABVD in older
patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11
Trials. J Clin Oncol 31 (2013) 1522-1529.
Karbach J, Gnjatic S, Biscamp M, Atmaca A, Weidmann E, Brandt K, Wahle C, Bernhard H, Knuth A, Jäger E.
Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain
metastasis: immunologic corralates. Cancer Immunol Res 2 (2014) 404-409.
Coiffier B, Federico M, Caballero D, Dearden C, Morschhauser F, Jäger U, Trümper L, Zucca E, Gomes da
Silva M, Pettengell R, Weidmann E, d‘Amore F, Tilly H, Zinzani PL. Therapeutic options in relapsed or
refractory peripheral T-cell lymphoma. Cancer Treatment Reviews 40 (2014) 1080-1088.
Bergmann L, Maute L, Heil G, Rüssel J. Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE,
Wörmann B, Hartung G, Moritz B, Edler L, Burkholder I, Scheulen ME, Richly H. A prospective randomised
phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer. A study of the
CESAR Central European Society for Anticancer Research-EWIV. Eur J Cancer 51 (2015) 27-36.
Kirschey S, Flohr T, Wolf HW, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N,
Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Rituximab combined with
DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell
lymphoma: mature results of a phase II multicentre study. Br J Haematology 168 (2015) 824-834.
Cheson Bruce D, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, Ogura M, Weidmann E, Wendtner CM, Zinzani PL. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an
international consenus panel – an update. Leuk Lymphoma 23 (2016) 766-752.
Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck H-P,
Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff Frank, Blau W,
Hinke A, Barth J. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed
indolent and mantle cell lymphomas: a multicentre, randomized, open-label, noninferiority phase 3 trial. Lancet
Oncol 17 (2016) 57-66.